Palatin Technologies: Funding, Investors & Team (Oct 2026)
Palatin Technologies is a company that specializes in the development of specific peptide therapeutics to address medical conditions in need of treatment options, while also holding commercial potential. The company's research focuses on manipulating the activity of melanocortin and natriuretic peptide receptor systems. Their main clinical product, bremelanotide, is aimed at providing a solution for female sexual dysfunction (FSD). Additionally, Palatin Technologies has various drug candidates and development programs targeting obesity, erectile dysfunction, pulmonary diseases, cardiovascular diseases, and inflammatory diseases. The company is currently directing their efforts towards designing and developing receptor-specific melanocortin agonists primarily for inflammation and autoimmune conditions, especially in ocular diseases. By utilizing endogenous melanocortin pathways, their therapeutics aim to alleviate damaging inflammation and facilitate the healing process. Notably, studies have indicated that melanocortin agonists have the potential to prevent and reverse inflammation in disease models, particularly in the eyes and intestine, which are among Palatin Technologies' areas of focus.
Palatin Technologies has raised $29.0M across 4 funding rounds on record, the most recent an undisclosed round of $18.2M announced in Nov 2025.
That round is above the $8.1M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Palatin Technologies Company Profile and Key Stats
Latest funding round on record: Nov 2025.
Palatin Technologies Funding Rounds
Palatin Technologies raised $5.0M in an undisclosed round announced in Oct 2023.
1.3 years later, an undisclosed round of $4.7M was announced in Feb 2025.
3 months later, an undisclosed round of $1.1M was announced in May 2025.
6 months later, an undisclosed round of $18.2M was announced in Nov 2025.
Palatin Technologies Founders and Leadership Team
Contact details for the Palatin Technologies team: 1 of 2 have an email address on file.
Start 14-day free trial →Palatin Technologies Funding Compared to Other Biotechnology Startups
Palatin Technologies' latest round of $18.2M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Palatin Technologies in Biotechnology and Cranbury
Companies Similar to Palatin Technologies
Kallyope, we believe that the gut is the gateway to our internal world. Containing millions of neurons, the…
Astrocyte Pharmaceuticals is a drug development company that helps in the recovery and well-being of brain…
Tiny Health offers a gut health test specifically designed for mothers and babies aged 0 to 3 years.…
Junevity is dedicated to using cutting-edge transcription factor medicines to combat age-related diseases.…
Arkea Bio creates technology aimed at reducing greenhouse gas (GHG) emissions in the agricultural sector.
Serán is a contract development and manufacturing organization providing a comprehensive suite of…
Precision’s goal is to provide breakthrough treatments for the one billion patients worldwide suffering from…
Enveda is a biotechnology company that utilizes AI-powered tools to explore and characterize molecules from…
Avery Therapeutics, Inc. is a company dedicated to developing tissue engineered therapeutics to treat…
Circle Pharma is a biotechnology company in the initial stages of development that uses unique computational…
Evvy is for people with vaginas who want to be empowered with information about their microbiome. Their…
Palatin Technologies Funding FAQs
What does Palatin Technologies do?
Palatin Technologies is a company that specializes in the development of specific peptide therapeutics to address medical conditions in need of treatment options, while also holding commercial potential. The company's research focuses on manipulating the activity of melanocortin and natriuretic peptide receptor systems. Their main clinical product, bremelanotide, is aimed at providing a solution for female sexual dysfunction (FSD). Additionally, Palatin Technologies has various drug candidates and development programs targeting obesity, erectile dysfunction, pulmonary diseases, cardiovascular diseases, and inflammatory diseases. The company is currently directing their efforts towards designing and developing receptor-specific melanocortin agonists primarily for inflammation and autoimmune conditions, especially in ocular diseases. By utilizing endogenous melanocortin pathways, their therapeutics aim to alleviate damaging inflammation and facilitate the healing process. Notably, studies have indicated that melanocortin agonists have the potential to prevent and reverse inflammation in disease models, particularly in the eyes and intestine, which are among Palatin Technologies' areas of focus.
How much funding has Palatin Technologies raised?
Palatin Technologies has raised $29.0M across 4 rounds on record. The most recent is an undisclosed round of $18.2M announced in Nov 2025.
When did Palatin Technologies last raise funding?
Palatin Technologies' most recent funding round on record is an undisclosed round of $18.2M, announced in Nov 2025.
Who founded Palatin Technologies?
FundedIQ lists Carl Spana (Founder), John Prendergast (Founder) at Palatin Technologies.
Where is Palatin Technologies headquartered?
Palatin Technologies is based in Cranbury, New Jersey, United States.
How many employees does Palatin Technologies have?
Palatin Technologies is in the 51-100 employee band.
How does Palatin Technologies' funding compare to other Biotechnology startups?
Palatin Technologies' latest round of $18.2M is above the $8.1M median round size for Biotechnology companies on FundedIQ across 4,185 tracked companies over the last two years.
About FundedIQ's Palatin Technologies Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Palatin Technologies is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Startup funding intelligence on every funded startup: the round, the investors and the founders, as a file in your inbox or searchable in the app.
Radar from $49/mo · Pro from $149/mo. Card required, nothing charged until day 15, and we email you 3 days before that. Need something specific? Custom plans from $499/mo.